Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Nebulised Delivery of BromAc® (Bromelain & Acetylcysteine) in Healthy Volunteers: a Potential Treatment for Severe COVID-19

NCT05220605 is registered in ClinicalTrials.gov with Mucpharm Pty Ltd as lead sponsor.

NCT NCT05220605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05220605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Nebulised Delivery of BromAc® (Bromelain & Acetylcysteine) in Healthy Volunteers: a Potential Treatment for Severe COVID-19
Lead sponsor
Mucpharm Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 27, 2022
Completion date
August 25, 2022
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acetylcysteine adverse reaction, bromelains adverse reaction, covid-19 acute respiratory distress syndrome, covid-19 pneumonia, mucus; plug